华丽家族：关于现金增资上海海和药物研究开发股份有限公司暨关联交易的进展公告

Core Points - The company Huayi Family announced an investment of RMB 299,999,996.50 (RMB 4.75 per share) to subscribe for 63,157,894 new shares of Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. [1] - This capital increase constitutes a related party transaction as Haihe Pharmaceutical is a subsidiary of the company's controlling shareholder, Shanghai Nanjing Group [1] - As of the announcement date, Nanjing Group holds approximately 11.54% of Haihe Pharmaceutical's shares directly and indirectly through its subsidiary, Tibet Nanjing Enterprise Management Consulting Co., Ltd. [1] - The investment agreement was formalized through a supplementary agreement signed on September 25, 2025, involving Nanjing Group, Tibet Nanjing, and Haihe Pharmaceutical [1]